We are live on ! Find out more
JNP

Juniper Pharmaceuticals, Inc. Common Stock
JNP

Delisted

JNP was delisted on the 13th of August, 2018.

Back to rankings

0 hedge funds and large institutions have $0 invested in Juniper Pharmaceuticals, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 48 → 0 (-48)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $44.1M → $0 (-$44.1M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 47

Holders
–
Holders Change
-48
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
47
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$6.54M
2
JAM
JW Asset Management
Florida
-$3.71M
3
BlackRock
BlackRock
New York
-$3.65M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$3.52M
5
BCM
Bridgeway Capital Management
Texas
-$3.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
California Public Employees Retirement System
26
California Public Employees Retirement System
California
– -$231K -26,574 Closed
JP Morgan Chase
27
JP Morgan Chase
New York
– -$143K -16,430 Closed
Simplex Trading
28
Simplex Trading
Illinois
– -$134K -15,474 Closed
Macquarie Group
29
Macquarie Group
Australia
– -$128K -14,758 Closed
Citadel Advisors
30
Citadel Advisors
Florida
– -$119K -13,635 Closed
PAM
31
Panagora Asset Management
Massachusetts
– -$93K -10,685 Closed
Bank of Montreal
32
Bank of Montreal
Ontario, Canada
– -$80K -9,298 Closed
TRCT
33
Tower Research Capital (TRC)
New York
– -$74K -8,488 Closed
Morgan Stanley
34
Morgan Stanley
New York
– -$66K -7,649 Closed
Russell Investments Group
35
Russell Investments Group
United Kingdom
– -$63K -7,084 Closed
Wells Fargo
36
Wells Fargo
California
– -$30K -3,400 Closed
CF
37
Centaurus Financial
California
– -$29K -3,300 Closed
PNC Financial Services Group
38
PNC Financial Services Group
Pennsylvania
– -$22K -2,500 Closed
SPIA
39
Steward Partners Investment Advisory
New York
– -$19K -2,150 Closed
Bank of America
40
Bank of America
North Carolina
– -$16K -1,900 Closed
PCM
41
Prelude Capital Management
New York
– -$10K -1,097 Closed
Federated Hermes
42
Federated Hermes
Pennsylvania
– -$8K -903 Closed
UBS Group
43
UBS Group
Switzerland
– -$6K -660 Closed
CMBA
44
C.M. Bidwell & Associates
Hawaii
– -$2K -270 Closed
FWM
45
Focused Wealth Management
New York
– -$1K -125 Closed
1
2

JNP Hedge Fund Activity: Q3 2018 in Review

0 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q3 2018, worth a combined $0 — down 100% from $44.1M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of JNP and 0 opened new positions — a net loss of 47 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Renaissance Technologies, exiting entirely with an estimated $6.54M sold.

  • 0 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q3 2018, down from 48 in Q2 2018.
  • Funds reported $0 of Juniper Pharmaceuticals, Inc. Common Stock stock for Q3 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 47 closed out, a net change of -47 holders.
  • The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Renaissance Technologies, an estimated $6.54M sold.

Based on aggregated 13F filings for Q3 2018.